Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis.

  title={Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis.},
  author={Jara Schulze and Insa Neumann and Michelle Magid and Eric Finzi and Christopher Sinke and Marc Axel Wollmer and Tillmann H. C. Kr{\"u}ger},
  journal={Journal of psychiatric research},
Treatment of Depression with Botulinum Toxin
The current status of the clinical development of BoNT as an antidepressant is described and an outlook on its potential future role in the management of mental disorders is given.
Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: A randomized controlled trial
Background: Inhibition of frowning via injections of botulinum toxin A (BTX) into the glabellar region has shown beneficial effects in the treatment of major depression. Preliminary research suggests
Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety
It is found that, compared to alternative treatments, BoNT injections were associated with lower incidence of anxiety symptoms and related disorders, and these findings are encouraging for possible future RCTs on the use of BoNT as a treatment for anxiety andrelated disorders.
Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective
Fundamental questions remain regarding the future prospects of BoNT/A therapy, including safety, efficacy, dose-response relationships, identification of potential predictors of response, and the precise mechanisms underlying BoNT-A therapy.
Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update
A method has been devised to induce a rapid molecular evolution of the metalloprotease domain of botulinum neurotoxin followed by selection driven to re-target the metallspinease activity versus novel targets with respect to the SNARE proteins.
Long‐term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis
Evaluated the adherence to repeated BoNTA over a period of five years, while secondary objectives included the assessment of its long‐term safety/efficacy and patients’ satisfaction to treatment.
Epidemiological aspects of poisoning Infectious-toxic bacteria of botulism on food poisoning in Iran; A review study
Food botulism is a rare neuroparalytic syndrome, caused by a neurotoxin produced by bacteria of the genus Clostridium, and botulinum neurotoxin is involved in the management and control of many diseases, dermatitis such as psoriasis, as well as in the beauty and elimination of facial skin wrinkles.
Anatomical Injection Guidelines for Glabellar Frown Lines Based on Ultrasonographic Evaluation
Dynamic muscle movements under ultrasonography (US) is examined and evaluated, thereby providing more effective BoNT injection guidelines for glabellar frowning and providing novel anatomical findings related to the injection of glabeller frown lines with BoNT.
Has the COVID‐19 pandemic changed attitudes and behaviors concerning cosmetic care and procedures among patients presenting to the dermatology outpatient clinic? A multicenter study with 1437 participants
The rate of cosmetic procedures and use of skincare products is considered to be affected during the pandemic period; however, this has not been investigated yet.


Role of Botulinum Toxin in Depression
This study suggests that botulinum toxin A can produce significant improvement in depressive symptoms and is a safe adjunctive treatment for patients receiving pharmacotherapy for depression.
Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials.
Equalling the status of a meta-analysis, this study increases evidence that a single treatment of BTA into the glabellar region can reduce symptoms of MDD.
Facing depression with botulinum toxin: a randomized controlled trial.
Botulinum Toxin as a Treatment for Depression in a Real-world Setting
It is suggested that glabellar BTX injection may also be effective in the treatment of severe depression and in the Treatment of depression in men, when treatment is carried out not just in clinical trials but in real-world settings.
Treatment of Depression with Botulinum Toxin A: A Case Series
  • E. Finzi, Erika L. Wasserman
  • Medicine, Psychology
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2006
These are the first reported cases of depression treated with botulinum toxin A in treating patients with major depression, and 9 of 10 patients were no longer depressed 2 months after treatment.
Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
Botulinum toxin A injection in the glabellar region was associated with significant improvement in depressive symptoms and may be a safe and sustainable intervention in the treatment of MDD.
Does Blocking Facial Feedback Via Botulinum Toxin Injections Decrease Depression? A Critical Review and Meta-Analysis
Researchers have proposed that blocking facial feedback via glabellar-region botulinum toxin injections (GBTX) can reduce depression. Random-effects meta-analyses of studies that administered GBTX to
Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials
A meta-analysis of prospective, placebo-controlled, double-blind trials of botulinum toxin type A shows that a single 20-unit dose is considered remarkably effective and safe for the treatment of glabellar lines.
Satisfaction of Patients After Treatment With Botulinum Toxin for Dynamic Facial Lines
Injections with BTX-A is a satisfying and well-tolerated treatment of dynamic facial lines for all patients in this pilot study.